

the Duke Clinical Research Unit (DCRU); and Krishna Udayakumar, MD, MBA, director of Duke Medicine Global.

The Medanta team was led by Dr. Naresh Trehan, founder, chairman and managing director of Medanta-The Medicity; Dr. Sanjay Mittal, director of clinical cardiology and research at Medanta; and Mr. Anil Virmani, chief financial officer of Medanta.

“This collaboration with Duke is a landmark event for India and Medanta in the direction of developing a center of excellence. Our shared goal is the safe and rapid development of therapies targeted at significant health problems,” said Trehan. “We hope that our partnership will produce research that will enable development of drugs and devices to improve health in India and around the globe.”

“These agreements create a significant opportunity to shift the paradigm for developing drugs and devices, and to collaborate for the achievement of a better understanding of human biology by using cutting-edge technologies and informatics,” said Califf. “A fundamental change in the way we study and develop drugs and devices is much-needed and long overdue.”

“I am truly proud of the partnership Medanta-The Medicity and Duke Medicine have created today,” said Victor J. Dzau, MD, chancellor for Health Affairs, Duke University, and CEO of Duke University Health System. “Ours is a shared vision of pursuing innovative approaches for the translation of clinical research into outcomes that serve the delivery of health care around the world, and MDRI stands as a testament to our commitment to making that happen.”

The MDRI facility will occupy a 27,000-square-foot space at Medanta -The Medicity comprising 60-beds and is expected to open in mid- April 2011. Tal Burt, MD previously associate professor for clinical research at Duke-National University of Singapore Graduate Medical School and director of the SingHealth Investigational Medicine Unit (IMU), serves as interim medical director for MDRI.

MDRI will leverage technologies and apply systems biology and molecular medicine to clinical research, with the goal of transforming the global framework for clinical development and evaluation of human biology, diseases, drugs and devices. The MDRI will adhere strictly to highest global standards for research quality as well as human subject protection in clinical studies.

“This partnership between Medanta and Duke would enable cutting edge technology and knowledge transfer to India, which will catalyze the development of new therapies for a large number of diseases,” said Mittal. “By performing ‘proof of concept’ studies, the MDRI will provide opportunities for Indian physicians and patients to participate in the clinical research process in ways that have not been previously possible.”

“With our significant experience in early phase clinical trials, DCRU looks forward to working with MDRI as this important next chapter opens in Duke Medicine’s global vision of improving clinical research,” said Sundry. “In collaborating with the DCRU and with the IMU in Singapore, MDRI will be positioned to simultaneously conduct early phase clinical trials and to participate